BRAIN TUMOR BIOREPOSITORY, HISTOPATHOLOGY, AND IMMUNOLOGIC MONITORING

脑肿瘤生物样本库、组织病理学和免疫学监测

• 批准号: 8106242
• 负责人: ROGER E MCLENDON
• 金额: $ 19.4万
• 依托单位: DUKE UNIVERSITY
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8106242
• 关键词: Adverse event; Arts; Autopsy; Bioinformatics; Biological Assay; Biopsy; Blood; Brain; Brain Neoplasms; Cancer Vaccines; Cataloging; Catalogs; Chondroitin Sulfate Proteoglycan; Classification; Clinical; Clinical Trials; Collaborations; Cytogenetics; DNA; Data; Data Set; Databases; Development; Diagnostic; Doctor of Medicine; Doctor of Philosophy; Eligibility Determination; Enrollment; Epidermal Growth Factor Receptor; Epilepsy; Flow Cytometry; Freezing; Funding; Genetic; Glioblastoma; Glioma; Grant; Histologic; Histopathology; Housing; Human; Human Herpesvirus 4; Human Resources; Immune response; Immunologic Monitoring; Immunologics; Immunology; Immunophenotyping; In Vitro; Individual; Instruction; Laboratories; Link; Lymphocyte; Malignant Glioma; Malignant neoplasm of brain; Manuscripts; Measures; Methyltransferase; Modeling; Molecular; National Institute of Neurological Disorders and Stroke; Nautilus; Neoplasm Metastasis; Outcome; Pathologic; Patients; Peer Review; Performance; Peripheral; Population; Principal Investigator; Process; Program Evaluation; RNA; Relative (related person); Research; Research Ethics Committees; Research Personnel; Resistance; Sampling; Serum; Somatic Cell; Sorting - Cell Movement; Source; Specimen; Staining method; Stains; Standardization; T-Lymphocyte; TNFRSF5 gene; Testing; Therapeutic; Tissue Banking; Tissue Banks; Tissues; Toxic effect; Training; Translations; Trauma; Tumor Tissue; United States National Institutes of Health; Vaccines; Work; Writing; base; biobank; brain tissue; cytokine; disorder control; experience; glycoprotein NMB; immune function; in vivo; neurosurgery; novel; peripheral blood; pre-clinical; preclinical study; programs; repository; response; success; treatment response; working group

Core B. Brain Tumor Biorepository, Histopathology, and Immunologic Monitoring Core. Roger McLendon, M.D., Core Leader The access to appropriately procured tissue (brain tumor, normal brain, and matched somatic cells) has been fundamental to the success of this NINDS Specialized Research Center on Primary and Metastatic Tumors of the CMS since its inception 25 years ago. This Biorepository has successfully obtained and sorted brain tumor tissue and matched peripheral somatic cells from more than 800 individual brain tumor patients with a net accumulation of more than 6,750 blocks of gliomas tissue. The Duke Immunologic Monitoring component of this Core will provide a variety of standard and in-house developed polychromatic flow cytometric assays of immune function, including intracellular cytokine staining and degranulation within a broad range of phenotypically-defmed T-cell populations on patients in Project 1. The Database component of this Core will store data from the genetic, cytogenetic, immunohistochemical, histologic and diagnostic analyses of all banked brain tumor tissues as well as normal brain samples in the Biorepository and furnish data to researchers requiring these data working in Projects 1, 2, and 3 and the IND, Regulatory, and Bioinformatics Core under Duke IRB oversight. This Core's Specific Aims will support the clinical and preclinical studies described in Projects 1, 2, and 3: 1) Provide and maintain a clinically annotated and catalogued biorepository of human brain tumor tissue, normal human brain tissue, and matched somatic cells from all brain tumor patients in clinical trials in Projects 1, 2, and 3; The Repository has a Nautilus database that will be linked to a clinical Oracle database in which all patients on a clinical trial in Projects 1, 2, and 3 will be entered; 2) Maintain access for scientific questions relative to Projects 1, 2, and 3 for the more than 800 brain tumor patient specimens and their matched somatic ceils entered into this Repository since the inception of this P50 grant in the early 1980s; 3) Provide integrated pathologic, histologic, immunohistochemical, and molecular diagnostic studies for Projects 1, 2, and 3, which will be entered into the Biorepository Nautilus database and linked to the Oracle clinical database for each patient; 4) Provide comprehensive immunologic monitoring of patients enrolled in clinical trials in Projects 1, 2, and 3, using highly standardized/validated state-of-the-art flow cytometry-based assays. RELEVANCE (See instructions): The availability of brain tumor tissue is necessary to determine the eligibility of patients for the clinical trials. Most of the new treatments depend on demonstrating specific molecules in each patient's brain tumor in order to enroll the patient in the appropriate clinical trial. The vaccine studies for malignant gliomas require immunologic monitoring of the responses to the vaccine treatment.

核心B。脑肿瘤生物库、组织学和免疫学监测中心。罗杰·麦克伦登 医学博士，核心领导 获得适当获取的组织（脑肿瘤、正常大脑和匹配的体细胞）已经 是这个NINDS原发性和转移性肿瘤专业研究中心成功的基础。 CMS的肿瘤自25年前成立以来。该生物储存库已成功获得， 从800多个脑肿瘤个体中分选脑肿瘤组织和匹配的外周体细胞 患者的神经胶质瘤组织净积累超过6,750块。杜克免疫学 该核心的监测组件将提供各种标准和内部开发的多色 免疫功能的流式细胞术测定，包括细胞内细胞因子染色和细胞内脱颗粒 在项目1中的患者上广泛的表型定义的T细胞群体。数据库 该核心的组成部分将存储来自遗传学、细胞遗传学、免疫组化、组织学和 对生物储存库中所有储存的脑肿瘤组织以及正常脑样本进行诊断分析 并向需要这些数据的研究人员提供数据，这些数据用于项目1，2和3以及IND，监管， 和生物信息学核心在杜克IRB的监督下。 该核心的具体目标将支持项目1、2和3中描述的临床和临床前研究： 1)提供并维护一个临床注释和编目的人脑肿瘤组织生物储存库， 正常人脑组织和来自所有脑肿瘤患者的匹配体细胞， 项目1、2和3;存储库有一个Nautilus数据库，将链接到临床Oracle数据库 在项目1、2和3的临床试验中，所有患者都将进入; 2）保持科学的访问权， 与项目1、2和3相关的问题，800多例脑肿瘤患者标本及其 自20世纪80年代初P50资助开始以来，进入该储存库的匹配体细胞; 3） 提供综合的病理学、组织学、免疫组化和分子诊断研究， 项目1、2和3，将输入Nautilus生物储存库数据库，并与Oracle数据库链接。 每个患者的临床数据库; 4）为入组的患者提供全面的免疫学监测 项目1、2和3中的临床试验，使用高度标准化/经验证的最先进的基于流式细胞术的 测定。 相关性（参见说明）： 脑肿瘤组织的可用性对于确定患者参加临床试验的资格是必要的。 大多数新的治疗方法都依赖于证明每个病人脑肿瘤中的特定分子， 以便将患者纳入适当的临床试验。恶性神经胶质瘤的疫苗研究需要 对疫苗治疗反应的免疫监测。